Hu5F9, an immune checkpoint inhibitor blocking CD47, has showed promise in working together with rituximab to eliminate non-Hodgkin lymphoma cells. A recent study looked to evaluate the drug in combination with rituximab in a clinical setting.
Hu5F9, an immune checkpoint inhibitor blocking CD47, has showed promise in working together with rituximab to eliminate non-Hodgkin lymphoma cells. A recent study looked to evaluate the combination therapy in a clinical setting.
Researchers conducted a phase 1B study that enrolled 22 patients with relapsed or refractory Hodgkin lymphoma. Hu5F9 was administered intravenously at a priming dose of 1 mg per kg of body weight, with a weekly maintenance dose of 10 mg to 30 mg per kg together with rituximab in order to allow for the evaluation of safety and efficacy in suggesting a phase 2 dose.
Of the 22 patients enrolled, 15 had diffuse large B-cell lymphoma (DLBCL) and 7 had follicular lymphoma. Patients had received a median of 4 (range, 2-10) prior therapies, and 95% of the patients had disease that was refractory to rituximab. The most common adverse events seen in the trial were anemia and infusion-related reactions.
In total, 50% of patients demonstrated an objective response to the therapy, with 36% experiencing a complete response. The rates of objective response and complete response were 40% and 33%, respectively, among patients with DLBCL and 71% and 43%, respectively, among patients with follicular lymphoma. Additionally, at a median follow-up of 6.2 months among patients with DLBCL and 8.1 months in patients with follicular lymphoma, researchers noted that 91% of the responses were ongoing.
Overall, the study authors reported that “The macrophage checkpoint inhibitor [Hu5F9] combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma.” Furthermore, the authors found that there were no clinically significant safety events demonstrated in the trial.
Reference
Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5f9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711-1721. doi: 10.1056/NEJMoa1807315.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.